title: Intralesional adalimumab for the treatment of refractory balanitis xerotica obliterans.
authors: Department of Dermatology, Mount Sinai Medical Center, New York, New York 10029, USA.
authors: Elie B
authors: EB
authors: Lowenstein
authors: Joshua A
authors: JA
authors: Zeichner
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D052798:Balanitis Xerotica Obliterans / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab